Five years after COVID, pharma shares languish in US policy limbo

Global healthcare stocks are trading at multi-decade lows, with an average 15.9x forward earnings multiple representing a 20% discount to global equities, primarily due to persistent uncertainty surrounding potential U.S. drug pricing policies and import tariffs. Despite recent fund inflows and long-term growth drivers like an aging population and innovation, the sector has significantly underperformed, leaving investors cautious and awaiting a clear policy catalyst to overcome the regulatory fog and trigger a broad re-rating.

Analysis

Global healthcare stocks are trading at historically low valuations, with the sector's forward price-to-earnings multiple of 15.9x representing a 20% discount to global equities, the steepest in 16 years. This significant de-rating, which has seen U.S. healthcare underperform the S&P 500 by over 60 percentage points in the last three years, is primarily driven by investor uncertainty regarding potential U.S. policy changes, including revived "most-favored-nation" drug pricing rules and tariffs. Despite these headwinds, contrarian indicators are emerging; fund inflows have turned positive since the start of 2024, and some investors are selectively increasing exposure, citing strong cash-flow yields and long-term drivers like aging populations and therapeutic breakthroughs. However, the market consensus remains cautious, viewing the sector as cheap but lacking a clear catalyst for a re-rating. Key triggers to watch include greater clarity on U.S. policy, which could unlock M&A activity, and potential interest rate cuts, which would lower R&D funding costs and increase the present value of future earnings.

Key Decisions for Investors

• Investors should weigh the sector's deep valuation discount against the unquantified risk of U.S. drug pricing and tariff policies, which currently acts as a significant impediment to a broad re-rating.
• Consider a selective approach, potentially favoring smaller, innovative firms like Alnylam and Penumbra that are transitioning to profitability, or established players like AstraZeneca making strategic U.S. investments to mitigate geopolitical risk.
• Monitor for two primary catalysts that could shift sentiment: any definitive clarification from Washington on future drug pricing policy and the timing of central bank interest rate cuts, which would be broadly positive for the sector.
• Be cautious of firm-specific risks even within the cheap sector, as exemplified by Novo Nordisk's 55% share price drop due to competitive pressures in the obesity drug market.